Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methotrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 5/20 | 0.98 |
| ▸ | FPGS | Q05932 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | TLR4 | O00206 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | TYMS | P04818 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.98 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.98 |
| ▸ | GART | P22102 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methotrexate SCHEMBL28339905 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL947900 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL29349432 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL171251 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL20548444 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3712 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL8216266 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL2301949 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3711 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL16013534 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113116842-A | Stomach retention tablet | 广州玻思韬控释药业有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-113116841-A | Stomach retention tablet | 广州玻思韬控释药业有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-113116851-A | Stomach retention tablet | 广州玻思韬控释药业有限公司 | 2021-07-16 | — | — | CN | claimed |
| CN-113444086-B | Ezh2 inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117881447-A | Formation of injector device stop features | W.L.戈尔及同仁股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117881445-A | Injector device stopper with activatable layer | W.L.戈尔及同仁股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117881444-A | Reshaping of injector device stopper features | W.L.戈尔及同仁股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117881446-A | Injector device component surface modification | W.L.戈尔及同仁股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-110913861-B | Morphological forms of G1T38 and methods of making the same | G1治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-116761795-A | Inhibitors of Transcription Enhancement Associated Domain (TEAD) and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116157403-A | Morphology of treasiril and method for producing same | G1治疗公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20070258889-A1 | NOVEL NANOPARTICLES AND USE THEREOF | MONTANA STATE UNIVERSITY (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070059245-A1 | Protein cages for the delivery of medical imaging and therapeutic agents | MONTANA STATE UNIVERSITY | 2007-03-15 | — | — | US | disclosed |
| US-20060204444-A1 | Protein cages for the delivery of medical imaging and therapeutic agents | MONTANA STATE UNIVERSITY NATIONAL INSTITUTE OF HEALTH | 2006-09-14 | — | — | US | disclosed |
| US-20040115132-A1 | Protein cages for the delivery of medical imaging and therapeutic agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-06-17 | — | — | US | disclosed |
| US-20040071765-A1 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO., LTD. | 2004-04-15 | — | — | US | disclosed |
| US-6597947-B1 | Iontophoresis device | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2003-07-22 | — | — | US | disclosed |
| EP-1177813-A1 | IONTOPHORESIS DEVICE | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1080731-A2 | Composition and device structure for iontophoresis | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-4374987-A | FROM 2,4,5,6-TETRAMINOPYRIMIDINE SULFATE, 1,1,3-TRIBROMOACETONE AND A ZINC P-AMINOBENZOYLGLUTAMATE | AMERICAN CYANAMID COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258889-A1 | NOVEL NANOPARTICLES AND USE THEREOF | EEA1, RAB5IF, CD47 | DHFR 3985/4885FPGS 4334/4885KDM4E 4300/4885 |
| US-20040071765-A1 | Composition and device structure for iontophoresis | ASIC1, AQP1, PIEZO1 | DHFR 3913/4885FPGS 3725/4885KDM4E 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.